Donatella Grasso

Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases

Daniele Santini, Giuseppe Perrone, Ilaria Roato et al. · Journal of Cellular Physiology · 2010 · 122 citations · Full text

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2019 · 111 citations · Full text

Metastatic Breast Cancer, Breast Oncology, Medicine +7

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 86 citations · Full text

Endocrine Oncology, Breast Oncology, Medicine +7

Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial

Lucia Del Mastro, Francesca Poggio, Eva Blondeaux et al. · The Lancet Oncology · 2022 · 46 citations

End-of-study Results, Breast Oncology, Early-stage Breast Cancer +6

Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study

Matteo Lambertini, Arlindo R. Ferreira, Antonio Di Meglio et al. · Clinical Breast Cancer · 2017 · 33 citations

Nursing, Breast Oncology, Medicine +7